 Jacob Pellinen
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsies, Partial | 16 | 2026 | 63 | 7.930 |
Why?
| | Seizures | 17 | 2026 | 482 | 4.430 |
Why?
| | Epilepsy | 13 | 2026 | 390 | 4.380 |
Why?
| | Anticonvulsants | 8 | 2026 | 246 | 3.380 |
Why?
| | Drug Resistant Epilepsy | 3 | 2026 | 138 | 2.090 |
Why?
| | Carbamates | 2 | 2026 | 50 | 1.800 |
Why?
| | Chlorophenols | 2 | 2026 | 12 | 1.180 |
Why?
| | Tetrazoles | 2 | 2026 | 50 | 1.160 |
Why?
| | Cognition | 2 | 2025 | 1262 | 0.980 |
Why?
| | Neuropsychological Tests | 3 | 2025 | 1134 | 0.900 |
Why?
| | Inappropriate Prescribing | 1 | 2026 | 66 | 0.900 |
Why?
| | Epilepsy, Generalized | 2 | 2021 | 22 | 0.870 |
Why?
| | Neurology | 1 | 2025 | 116 | 0.790 |
Why?
| | Migraine Disorders | 1 | 2024 | 114 | 0.720 |
Why?
| | Status Epilepticus | 1 | 2022 | 68 | 0.670 |
Why?
| | Malformations of Cortical Development | 1 | 2020 | 19 | 0.640 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2021 | 75 | 0.620 |
Why?
| | Brain Diseases | 1 | 2020 | 154 | 0.580 |
Why?
| | Artificial Intelligence | 1 | 2024 | 381 | 0.580 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 343 | 0.560 |
Why?
| | Young Adult | 11 | 2026 | 14176 | 0.540 |
Why?
| | Delayed Diagnosis | 3 | 2025 | 100 | 0.530 |
Why?
| | Electroencephalography | 5 | 2025 | 561 | 0.480 |
Why?
| | Quality Improvement | 1 | 2025 | 1293 | 0.470 |
Why?
| | Adult | 16 | 2026 | 40665 | 0.460 |
Why?
| | Middle Aged | 13 | 2026 | 36126 | 0.420 |
Why?
| | Adolescent | 12 | 2026 | 22479 | 0.420 |
Why?
| | Humans | 31 | 2026 | 145140 | 0.410 |
Why?
| | Brain Chemistry | 1 | 2014 | 117 | 0.400 |
Why?
| | Lipoproteins | 1 | 2014 | 166 | 0.380 |
Why?
| | Physicians | 1 | 2021 | 954 | 0.380 |
Why?
| | Fatty Acid Synthases | 1 | 2012 | 23 | 0.360 |
Why?
| | 4-Butyrolactone | 1 | 2012 | 23 | 0.360 |
Why?
| | Brain | 1 | 2023 | 2934 | 0.330 |
Why?
| | Male | 15 | 2026 | 72664 | 0.320 |
Why?
| | Weight Gain | 1 | 2014 | 561 | 0.310 |
Why?
| | Comorbidity | 2 | 2026 | 1657 | 0.310 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 715 | 0.280 |
Why?
| | Female | 14 | 2026 | 78636 | 0.270 |
Why?
| | Retrospective Studies | 6 | 2026 | 17247 | 0.270 |
Why?
| | Emergency Service, Hospital | 3 | 2024 | 2377 | 0.230 |
Why?
| | Sleep | 2 | 2012 | 887 | 0.230 |
Why?
| | Electrocorticography | 1 | 2025 | 20 | 0.230 |
Why?
| | Efficiency | 1 | 2026 | 103 | 0.220 |
Why?
| | Age of Onset | 2 | 2025 | 554 | 0.220 |
Why?
| | Cerebellum | 1 | 2026 | 224 | 0.200 |
Why?
| | Syncope | 1 | 2024 | 56 | 0.200 |
Why?
| | Atrophy | 1 | 2023 | 198 | 0.190 |
Why?
| | Quality of Life | 3 | 2026 | 3194 | 0.190 |
Why?
| | Deep Brain Stimulation | 1 | 2026 | 217 | 0.180 |
Why?
| | Longevity | 1 | 2024 | 177 | 0.180 |
Why?
| | Organ Size | 1 | 2023 | 459 | 0.180 |
Why?
| | Cohort Studies | 4 | 2025 | 5988 | 0.170 |
Why?
| | Recurrence | 2 | 2025 | 1134 | 0.170 |
Why?
| | Neurophysiological Monitoring | 1 | 2020 | 9 | 0.160 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6055 | 0.160 |
Why?
| | Aged | 4 | 2026 | 26096 | 0.160 |
Why?
| | Prospective Studies | 4 | 2026 | 8035 | 0.160 |
Why?
| | New York | 1 | 2020 | 128 | 0.160 |
Why?
| | Internet | 1 | 2024 | 689 | 0.150 |
Why?
| | Child | 5 | 2025 | 22670 | 0.140 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 103 | 0.140 |
Why?
| | Anxiety | 1 | 2026 | 1117 | 0.140 |
Why?
| | Mental Health | 1 | 2025 | 791 | 0.140 |
Why?
| | Treatment Outcome | 2 | 2025 | 11741 | 0.130 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 363 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 271 | 0.120 |
Why?
| | Encephalitis | 1 | 2018 | 142 | 0.120 |
Why?
| | Depression | 1 | 2026 | 1537 | 0.120 |
Why?
| | Overweight | 1 | 2021 | 609 | 0.120 |
Why?
| | Tuberculosis | 1 | 2019 | 283 | 0.120 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 318 | 0.110 |
Why?
| | Nerve Tissue Proteins | 1 | 2018 | 589 | 0.110 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2014 | 154 | 0.100 |
Why?
| | Australia | 2 | 2026 | 287 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1703 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3892 | 0.100 |
Why?
| | Environment | 1 | 2014 | 293 | 0.090 |
Why?
| | Receptors, Ghrelin | 1 | 2011 | 7 | 0.090 |
Why?
| | Sleep Deprivation | 1 | 2014 | 206 | 0.090 |
Why?
| | Eating | 1 | 2014 | 387 | 0.080 |
Why?
| | Wakefulness | 1 | 2011 | 170 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2014 | 3114 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 7107 | 0.070 |
Why?
| | Genotype | 1 | 2014 | 1844 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 820 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2012 | 529 | 0.070 |
Why?
| | Animals | 5 | 2026 | 37952 | 0.070 |
Why?
| | Homeostasis | 1 | 2011 | 639 | 0.070 |
Why?
| | Mice | 3 | 2014 | 18303 | 0.060 |
Why?
| | Drug Approval | 1 | 2025 | 93 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2025 | 207 | 0.050 |
Why?
| | Morbidity | 1 | 2025 | 322 | 0.050 |
Why?
| | Habits | 1 | 2024 | 52 | 0.050 |
Why?
| | Motor Vehicles | 1 | 2023 | 30 | 0.050 |
Why?
| | Self-Injurious Behavior | 1 | 2025 | 141 | 0.050 |
Why?
| | Documentation | 1 | 2024 | 199 | 0.040 |
Why?
| | Carbamazepine | 1 | 2021 | 24 | 0.040 |
Why?
| | Accidents, Traffic | 1 | 2023 | 193 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 177 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 3097 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 431 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 288 | 0.040 |
Why?
| | Antibiotics, Antitubercular | 1 | 2019 | 35 | 0.040 |
Why?
| | Suicidal Ideation | 1 | 2025 | 577 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 639 | 0.040 |
Why?
| | Ophthalmoplegia | 1 | 2018 | 13 | 0.040 |
Why?
| | Rifampin | 1 | 2019 | 79 | 0.040 |
Why?
| | Blepharoptosis | 1 | 2018 | 13 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2026 | 2949 | 0.030 |
Why?
| | Gait Disorders, Neurologic | 1 | 2018 | 44 | 0.030 |
Why?
| | Coinfection | 1 | 2019 | 143 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 497 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3338 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1995 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3410 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2018 | 465 | 0.020 |
Why?
| | Ghrelin | 1 | 2011 | 42 | 0.020 |
Why?
| | Body Temperature | 1 | 2011 | 227 | 0.020 |
Why?
| | United States | 1 | 2025 | 16065 | 0.020 |
Why?
| | Motor Activity | 1 | 2011 | 718 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5972 | 0.010 |
Why?
|
|
Pellinen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|